The effect of synbiotic supplementation on glycemic factor, lipid profile, Total antioxidant capacity and serum inflammatory factors in patients with type 1 diabetes.

Determination of the Effect of Synbiotic Supplementation on Glycemic Factor, Lipid Profile, Total Antioxidant Capacity and Serum Inflammatory Factors in Patients with Type 1 Diabetes

In this double-blind trial study, 50 subjects were selected based on entry and exit criteria for participation in this study. Using simple random sampling, they were randomly divided into two groups of 25 intervention and control group.

This is a clinical trial study done on type 1 diabetic patients referred to an endocrinologist clinic in 1397. The proposed patients are coded by a third party health care provider who does not know anything about the research, and researchers and patients also do not have information about the contents of the packages.

Inclusion criteria: Type 1 diabetes. Exit criteria: Unwillingness to participate in the study, kidney disease, coronary arteries, acute and chronic lung inflammation, short stomach cyst syndrome, allergy, travel more than 2 weeks, smokers, use of food supplements, anti-inflammatory drugs, use of any antioxidant supplements in the last 3 months, use of medications Immune suppressants, follow special diets, change diet or decide to lose weight

Patients (50 people) are randomly divided into two groups of 25. In the intervention group, 1 gramme of synbiotic supplement from the Parsi Lakt Shiraz Company (cfu 109 Lactobacillus spurogenesis and cfu 1010 Bifidobacterium as probiotic and inulin as a periwist) with a glass of water once a day after lunch for a period of 8 weeks. In the control group, patients receive 1 g of starch with a glass of water once a day after lunch for 8 weeks.

Fasting blood glucose, serum insulin, HbA1c, lipid factor TG, Chol-T, LDL-c, HDL-c, total antioxidant capacity (TAC) and inflammatory factors

First of all, individuals who have the characteristics necessary to enter the study are usually taken from a non-random sample using a simple sampling method. Then, randomization is done between study groups. In this study, a block randomization method (block 4) is used. One of the study colleagues who did not have blindfolded, named synbiotic and placebo with the letters A and B (for example). Then, the researcher distributed A and B packages among the patients referring to the study in the office by random blocking (ABAB, BABA, AABB, ABBA, ABBA, BAAB) by randomized blocking (First person A, Second person B, third person A, fourth person B, ...). Then, blocks are created so that blocks are randomly selected to reach the required sample size.

To blind the study, it is given to a powder control group that is similar in appearance to the supplement in the treatment group (intervention), which has no effective substance (placebo or placebo). In this study, coding will be done by a third person from health care providers who do not know anything about this research, and researchers and patients will not be aware of the contents of the packets.